Emerging Therapeutic Targets for Spontaneous Intracerebral Hemorrhage

References

1. Seiffge D.J. Fandler-Höfler S. Du Y. Goeldlin M.B. Jolink W.M.T. Klijn C.J.M. Werring D.J. Intracerebral haemorrhage — mecha-nisms, diagnosis and prospects for treatment and prevention. Nat. Rev. Neurol. 2024 20 12 708 723 10.1038/s41582‑024‑01035‑w 39548285
   [Google Scholar]
2. Morris N.A. Simard J.M. Chaturvedi S. Surgical management for primary intracerebral hemorrhage. Neurology 2024 103 4 e209714 10.1212/WNL.0000000000209714 39074339
   [Google Scholar]
3. Chang C.F. Goods B.A. Askenase M.H. Hammond M.D. Renfroe S.C. Steinschneider A.F. Landreneau M.J. Ai Y. Beatty H.E. da Costa L.H.A. Mack M. Sheth K.N. Greer D.M. Huttner A. Coman D. Hyder F. Ghosh S. Rothlin C.V. Love J.C. Sansing L.H. Erythrocyte efferocytosis modulates macrophages towards recovery after intracerebral hemorrhage. J. Clin. Invest. 2017 128 2 607 624 10.1172/JCI95612 29251628
   [Google Scholar]
4. Röszer T. Transcriptional control of apoptotic cell clearance by macrophage nuclear receptors. Apoptosis 2017 22 2 284 294 10.1007/s10495‑016‑1310‑x 27787652
   [Google Scholar]
5. Wang G. Li T. Duan S. Dong L. Sun X. Xue F. PPAR-Ƴ promotes hematoma clearance through haptoglobin-hemoglobin-CD163 in a rat model of intracerebral hemorrhage. Behav. Neurol. 2018 2018 1 7 10.1155/2018/7646104
   [Google Scholar]
6. Gonzales N.R. Shah J. Sangha N. Sosa L. Martinez R. Shen L. Kasam M. Morales M.M. Hossain M.M. Barreto A.D. Savitz S.I. Lopez G. Misra V. Wu T.C. Khoury R.E. Sarraj A. Sahota P. Hicks W. Acosta I. Sline M.R. Rahbar M.H. Zhao X. Aro-nowski J. Grotta J.C. Design of a prospective, dose-escalation study evaluating the safety of pioglitazone for hematoma resolution in in-tracerebral hemorrhage (SHRINC). Int. J. Stroke 2013 8 5 388 396 10.1111/j.1747‑4949.2011.00761.x 22340518
   [Google Scholar]
7. Wan J. Ren H. Wang J. Iron toxicity, lipid peroxidation and ferroptosis after intracerebral haemorrhage. Stroke Vasc. Neurol. 2019 4 2 93 95 10.1136/svn‑2018‑000205 31338218
   [Google Scholar]
8. Selim M. Foster L.D. Moy C.S. Xi G. Hill M.D. Morgenstern L.B. Greenberg S.M. James M.L. Singh V. Clark W.M. Norton C. Palesch Y.Y. Yeatts S.D. Dolan M. Yeh E. Sheth K. Kunze K. Muehlschlegel S. Nieto I. Claassen J. Falo C. Huang D. Beckwith A. Messe S. Yates M. O’Phelan K. Escobar A. Becker K. Tanzi P. Gonzales N. Tremont C. Venkatasubramanian C. Thiessen R. Save S. Verrault S. Collard K. DeGeorgia M. Cwiklinski V. Thompson B. Wasilewski L. Andrews C. Burfeind R. Torbey M. Hamed M. Butcher K. Sivakumar L. Varelas N. Mays-Wilson K. Leira E. Olalde H. Silliman S. Calhoun R. Danga-yach N. Renvill R. Malhotra R. Kordesch K. Lord A. Calahan T. Geocadin R. Parish M. Frey J. Harrigan M. Leifer D. Mathi-as R. Schneck M. Bernier T. Gonzales-Arias S. Elysee J. Lopez G. Volgi J. Brown R. Jasak S. Phillips S. Jarrett J. Gomes J. McBride M. Aldrich F. Aldrich C. Kornbluth J. Bettle M. Goldstein J. Tirrell G. Shaw Q. Jonczak K. Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): A multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurol. 2019 18 5 428 438 10.1016/S1474‑4422(19)30069‑9 30898550
   [Google Scholar]
9. Foster L. Robinson L. Yeatts S.D. Conwit R.A. Shehadah A. Lioutas V. Selim M. i-DEF Investigators. Effect of deferoxamine on trajectory of recovery after intracerebral hemorrhage: A post hoc analysis of the i-DEF Trial. Stroke 2022 53 7 2204 2210 10.1161/STROKEAHA.121.037298 35306827
   [Google Scholar]
10. Fouda A.Y. Newsome A.S. Spellicy S. Waller J.L. Zhi W. Hess D.C. Ergul A. Edwards D.J. Fagan S.C. Switzer J.A. Minocy-cline in acute cerebral hemorrhage: An early phase randomized trial. Stroke 2017 48 10 2885 2887 10.1161/STROKEAHA.117.018658 28887388
    [Google Scholar]
11. Chang J.J. Kim-Tenser M. Emanuel B.A. Jones G.M. Chapple K. Alikhani A. Sanossian N. Mack W.J. Tsivgoulis G. Alexan-drov A.V. Pourmotabbed T. Minocycline and matrix metalloproteinase inhibition in acute intracerebral hemorrhage: A pilot study. Eur. J. Neurol. 2017 24 11 1384 1391 10.1111/ene.13403 28929560
    [Google Scholar]
12. Voigt S. Koemans E.A. Rasing I. van Etten E.S. Terwindt G.M. Baas F. Kaushik K. van Es A.C.G.M. van Buchem M.A. van Osch M.J.P. van Walderveen M.A.A. Klijn C.J.M. Verbeek M.M. van der Weerd L. Wermer M.J.H. Minocycline for sporadic and hereditary cerebral amyloid angiopathy (BATMAN): Study protocol for a placebo-controlled randomized double-blind trial. Trials 2023 24 1 378 10.1186/s13063‑023‑07371‑4 37277877
    [Google Scholar]
13. Parry-Jones A.R. Stocking K. MacLeod M.J. Clarke B. Werring D.J. Muir K.W. Vail A. Phase II randomised, placebo-controlled, clinical trial of interleukin-1 receptor antagonist in intracerebral haemorrhage: Blocking the cytokine IL-1 in ICH (BLOC-ICH). Eur. Stroke J. 2023 8 3 819 827 10.1177/23969873231185208 37452707
    [Google Scholar]
14. Cliteur M.P. van der Kolk A.G. Hannink G. Hofmeijer J. Jolink W.M.T. Klijn C.J.M. Schreuder F.H.B.M. Anakinra in cerebral haemorrhage to target secondary injury resulting from neuroinflammation (ACTION): Study protocol of a phase II randomised clinical tri-al. Eur. Stroke J. 2024 9 1 265 273 10.1177/23969873231200686 37713268
    [Google Scholar]
15. Fu Y. Hao J. Zhang N. Ren L. Sun N. Li Y.J. Yan Y. Huang D. Yu C. Shi F.D. Fingolimod for the treatment of intracerebral hemorrhage: A 2-arm proof-of-concept study. JAMA Neurol. 2014 71 9 1092 1101 10.1001/jamaneurol.2014.1065 25003359
    [Google Scholar]
16. A phase II, patient- and investigator-blinded, randomized, placebo-controlled study to evaluate efficacy, safety and tolerability of BAF312 (siponimod) in patients with stroke due to intracerebral hemorrhage (ICH). 2021 Available from: https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17824
17. Jiang B. Li L. Chen Q. Tao Y. Yang L. Zhang B. Zhang J.H. Feng H. Chen Z. Tang J. Zhu G. Role of glibenclamide in brain injury after intracerebral hemorrhage. Transl. Stroke Res. 2017 8 2 183 193 10.1007/s12975‑016‑0506‑2 27807801
    [Google Scholar]
18. Zhao J. Song C. Li D. Yang X. Yu L. Wang K. Wu J. Wang X. Li D. Zhang B. Li B. Guo J. Feng W. Fu F. Gu X. Qian J. Li J. Yuan X. Liu Q. Chen J. Wang X. Liu Y. Wei D. Wang L. Shang L. Yang F. Jiang W. Efficacy and safety of glibenclamide therapy after intracerebral haemorrhage (GATE-ICH): A multicentre, prospective, randomised, controlled, open-label, blinded-endpoint, phase 2 clinical trial. EClinicalMedicine 2022 53 101666 10.1016/j.eclinm.2022.101666 36177443
    [Google Scholar]
19. Chu K. Jeong S.W. Jung K.H. Han S.Y. Lee S.T. Kim M. Roh J.K. Celecoxib induces functional recovery after intracerebral hem-orrhage with reduction of brain edema and perihematomal cell death. J. Cereb. Blood Flow Metab. 2004 24 8 926 933 10.1097/01.WCB.0000130866.25040.7D 15362723
    [Google Scholar]
20. Lee S.H. Park H.K. Ryu W.S. Lee J.S. Bae H.J. Han M.K. Lee Y.S. Kwon H.M. Kim C.K. Park E.S. Chung J.W. Jung K.H. Roh J.K. Effects of celecoxib on hematoma and edema volumes in primary intracerebral hemorrhage: A multicenter randomized con-trolled trial. Eur. J. Neurol. 2013 20 8 1161 1169 10.1111/ene.12140 23551657
    [Google Scholar]
21. Marini S. Crawford K. Morotti A. Lee M.J. Pezzini A. Moomaw C.J. Flaherty M.L. Montaner J. Roquer J. Jimenez-Conde J. Giralt-Steinhauer E. Elosua R. Cuadrado-Godia E. Soriano-Tarraga C. Slowik A. Jagiella J.M. Pera J. Urbanik A. Pichler A. Hansen B.M. McCauley J.L. Tirschwell D.L. Selim M. Brown D.L. Silliman S.L. Worrall B.B. Meschia J.F. Kidwell C.S. Testai F.D. Kittner S.J. Schmidt H. Enzinger C. Deary I.J. Rannikmae K. Samarasekera N. Salman R.A-S. Sudlow C.L. Klijn C.J.M. van Nieuwenhuizen K.M. Fernandez-Cadenas I. Delgado P. Norrving B. Lindgren A. Goldstein J.N. Viswanathan A. Greenberg S.M. Falcone G.J. Biffi A. Langefeld C.D. Woo D. Rosand J. Anderson C.D. Association of apolipoprotein E with intracerebral hemorrhage risk by race/ethnicity. JAMA Neurol. 2019 76 4 480 491 10.1001/jamaneurol.2018.4519 30726504
    [Google Scholar]
22. Marchina S. Yeatts S.D. Foster L.D. Janis S. Shoamanesh A. Khatri P. Bernstein K. Perlmutter A. Stever C. Heistand E.C. Broderick J.P. Greenberg S.M. Leira E.C. Rosand J. Lioutas V.A. Salman R.A.S. Tirschwell D. Marti-Fabregas J. Selim M. Ra-tionale and design of the statin use in intracerebral hemorrhage patients (SATURN) trial. Cerebrovasc. Dis. 2024 Epub ahead of print 10.1159/000538195 38493765
    [Google Scholar]
23. Gao D. Chu X. Zhang Y. Yan H. Niu L. Jiang X. Bao S. Ji X. Wu C. Statins for neuroprotection in spontaneous intracerebral haemorrhage (STATIC): Protocol for a multicentre, prospective and randomised controlled trial. BMJ Open 2024 14 6 e079879 10.1136/bmjopen‑2023‑079879 38908848
    [Google Scholar]
24. Li M. Ren H. Sheth K.N. Shi F.D. Liu Q. A TSPO ligand attenuates brain injury after intracerebral hemorrhage. FASEB J. 2017 31 8 3278 3287 10.1096/fj.201601377RR 28416580
    [Google Scholar]
25. Zhang T. Xia F. Wan Y. Xi G. Ya H. Keep R.F. Complement inhibition reduces early erythrolysis, attenuates brain injury, hydro-cephalus, and iron accumulation after intraventricular hemorrhage in aged rats. Transl. Stroke Res. 2025 16 3 882 895 10.1007/s12975‑024‑01273‑6 38943026
    [Google Scholar]
26. Wang Z. Li Y. Wang Z. Liao Y. Ye Q. Tang S. Wei T. Xiao P. Huang J. Lu W. Edaravone maintains AQP4 polarity via OS/MMP9/b-DG pathway in an experimental intracerebral hemorrhage mouse model. Mol. Neurobiol. 2024 61 10 7659 7660 10.1007/s12035‑024‑04275‑5 38833129
    [Google Scholar]
27. Shi S.X. Li Y.J. Shi K. Wood K. Ducruet A.F. Liu Q. (Interleukin)-15 bridges astrocyte-microglia crosstalk and exacerbates brain injury following intracerebral hemorrhage. Stroke 2020 51 3 967 974 10.1161/STROKEAHA.119.028638 32019481
    [Google Scholar]
28. Gao Y. Ma L. Luo C. Wang T. Zhang M. Shen X. Meng H. Ji M. Wang Z. Chen X. Tao L. IL-33 exerts neuroprotective effect in mice intracerebral hemorrhage model through suppressing inflammation/apoptotic/autophagic pathway. Mol. Neurobiol. 2017 54 5 3879 3892 10.1007/s12035‑016‑9947‑6 27405469
    [Google Scholar]
29. Zhao X. Ting S.M. Liu C.H. Sun G. Kruzel M. Roy-O’Reilly M. Aronowski J. Neutrophil polarization by IL-27 as a therapeutic target for intracerebral hemorrhage. Nat. Commun. 2017 8 1 602 10.1038/s41467‑017‑00770‑7 28928459
    [Google Scholar]
30. Han R. Luo J. Shi Y. Yao Y. Hao J. PD-L1 (programmed death ligand 1) protects against experimental intracerebral hemorrhage-induced brain injury. Stroke 2017 48 8 2255 2262 10.1161/STROKEAHA.117.016705 28706113
    [Google Scholar]